Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers.

Purpose: The aim of the study was to determine the steady-state pharmacokinetics of metformin in healthy volunteers with different numbers of reduced-function alleles in the organic cation transporter 1 gene ( OCT1). Methods: The study was conducted as part of a randomized cross-over trial. Thirty-f...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 71; no. 6; pp. 691 - 698
Autores principales: Christensen, Mette, Højlund, Kurt, Hother-Nielsen, Ole, Stage, Tore, Damkier, Per, Beck-Nielsen, Henning, Brøsen, Kim
Formato: clinical trial research tables/charts Journal Article
Publicado: Springer Nature Jun2015
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Purpose: The aim of the study was to determine the steady-state pharmacokinetics of metformin in healthy volunteers with different numbers of reduced-function alleles in the organic cation transporter 1 gene ( OCT1). Methods: The study was conducted as part of a randomized cross-over trial. Thirty-four healthy volunteers with known OCT1 genotypes (12 with two wild-type alleles, 13 with one and 9 with two reduced-function alleles) were included. In one of the study periods, they were titrated to steady-state with 1 g metformin twice daily. Results: Neither AUC, C nor Cl were statistically significantly affected by the number of reduced-function alleles (0, 1 or 2) in OCT1: (AUC: 0, 1, 2: 14, 13 and 14 h ng/L ( P= 0.61)); ( C: 0, 1, 2: 2192, 1934 and 2233 ng/mL, ( P = 0.26)) and (Cl: 0, 1, 2: 31, 28 and 30 L/h ( P = 0.57)) Conclusions: In a cohort of healthy volunteers, we found no impact of different OCT1 genotypes on metformin steady-state pharmacokinetics.